Evidence map›Paper›PMID 39739807›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Tamsulosin ameliorates bone loss by inhibiting the release of Cl

Shiliang Li, Weijia Sun, Shuang Li, Lili Zhu, Shuai Guo, Jiaqi He, Yuheng Li, Chaoquan Tian, Zhenjiang Zhao, Tao Yu and 10 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Shiliang Li *Innovation Center for AI and Drug Discovery, School of Pharmacy, East China Normal University, Shanghai 200062, China.ORCID 0000-0003-4414-237X
Weijia Sun *National Key Laboratory of Space Medicine, China Astronaut Research and Training Center, Beijing 100094, China.ORCID 0000-0003-3604-6919
Shuang Li *Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.ORCID 0009-0006-4938-262X
Lili ZhuShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.ORCID 0000-0003-1957-973X
Shuai GuoSchool of Life Science, Hebei University, Baoding, Hebei 071000, China.ORCID 0000-0002-5342-9666
Jiaqi HeShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Yuheng LiNational Key Laboratory of Space Medicine, China Astronaut Research and Training Center, Beijing 100094, China.
Chaoquan TianShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Zhenjiang ZhaoShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Tao YuInnovation Center for AI and Drug Discovery, School of Pharmacy, East China Normal University, Shanghai 200062, China.ORCID 0000-0003-4809-8169
Jianwei LiNational Key Laboratory of Space Medicine, China Astronaut Research and Training Center, Beijing 100094, China.
Yiqing ZhangShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Youlong HaiDepartment of Urology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.ORCID 0000-0003-0742-6867
Jiawen WangShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Yongjun ZhengDepartment of Pain management, HuaDong Hospital affiliated to Fudan University, Shanghai 200040, China.
Rui WangShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Xiaoyong HuDepartment of Urology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
Shukuan LingOujiang Laboratory (Zhejiang Lab for Regenerative Medicine Vision and Brain Health), Wenzhou, Zhejiang 325603, China.ORCID 0000-0002-4622-4160
Honglin LiInnovation Center for AI and Drug Discovery, School of Pharmacy, East China Normal University, Shanghai 200062, China.ORCID 0000-0003-2270-1900
Yingxian LiNational Key Laboratory of Space Medicine, China Astronaut Research and Training Center, Beijing 100094, China.ORCID 0000-0002-5440-3281

Funding

MOST | National Key Research and Development Program of China (NKPs) 2022YFC3400501MOST | National Key Research and Development Program of China (NKPs) 2022YFC3400504MOST | National Natural Science Foundation of China (NSFC) 82150208MOST | National Natural Science Foundation of China (NSFC) 82173690MOST | National Natural Science Foundation of China (NSFC) 82192880MOST | National Natural Science Foundation of China (NSFC) 82192882MOST | National Natural Science Foundation of China (NSFC) 82425104Shanghai Rising-Star Program 23QA1402800
6 · The paper itself

Abstract

TMEM16A, a key calcium-activated chloride channel, is crucial for many physiological and pathological processes such as cancer, hypertension, and osteoporosis, etc. However, the regulatory mechanism of TMEM16A is poorly understood, limiting the discovery of effective modulators. Here, we unveil an allosteric gating mechanism by presenting a high-resolution cryo-EM structure of TMEM16A in complex with a channel inhibitor that we identified, Tamsulosin, which is resolved at 2.93 Å. Tamsulosin wedges itself into a pocket within the extracellular domain of TMEM16A, surrounded by α1-α2, α5-α6, and α9-α10 loops. This binding stabilizes a transient preopen conformation of TMEM16A, which is activated by Ca

Indexed as

Allosteric SiteAnoctamin-1TamsulosinAllosteric RegulationAnimalsBinding SitesChloridesCryoelectron MicroscopyHEK293 CellsHumansMiceNeoplasm ProteinsOsteoporosisANO1 protein, humanAnoctamin-1ChloridesNeoplasm ProteinsTamsulosinallosteric sitebone lossTamsulosinTMEM16A

Identifiers

PMID39739807
PMCPMC11725887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.